These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15548436)

  • 1. Chemotherapy in hormone refractory prostate cancer: where do we stand?
    Clarke NW; Wylie JP
    Eur Urol; 2004 Dec; 46(6):709-11. PubMed ID: 15548436
    [No Abstract]   [Full Text] [Related]  

  • 2. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer.
    Higgins GS; Stewart GD; McNeill SA; McLaren DB
    Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800
    [No Abstract]   [Full Text] [Related]  

  • 3. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".
    Ryan CJ; Eisenberger M
    J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 6. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
    Ghosn M; Kattan J; Younes F
    Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
    Uzzo RG; Haas NB; Crispen PL; Kolenko VM
    Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the hormone sensitivity of prostate cancer: where are we now?
    Alcaraz A
    Eur Urol; 2008 Aug; 54(2):247-50; discussion 250-1. PubMed ID: 18343562
    [No Abstract]   [Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of hormonal refractory metastatic prostate cancer].
    Sengeløv L; Klarskov OP; Karlsson S
    Ugeskr Laeger; 2007 May; 169(20):1905-7. PubMed ID: 17553368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
    Schally AV
    BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment with prednisolone of hormone-refractory prostate cancer.
    Fuse H; Nozaki T; Fujiuchi Y; Mizuno I; Nagakawa O; Okumura A
    Arch Androl; 2006; 52(1):35-8. PubMed ID: 16338867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current role of chemotherapy in the treatment of hormone-resistant prostatic cancer].
    Soulie M; Beuzeboc P; Irani J; Davin JL
    Prog Urol; 2006 Jun; 16(3):394-5. PubMed ID: 16821362
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dexamethasone for hormone refractory prostate cancer].
    Nounaka O; Sato S; Shinohara N; Koyanagi T; Demura T
    Nihon Rinsho; 2000 Jul; 58 Suppl():343-6. PubMed ID: 11022746
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 18. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
    D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
    J Urol; 2005 May; 173(5):1572-6. PubMed ID: 15821488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.